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a b s t r a c t
For almost 150 years after Edward Jenner had published the ‘‘Inquiry” in 1798, it was generally assumed
that the cowpox virus was the vaccine against smallpox. It was not until 1939 when it was shown that
vaccinia, the smallpox vaccine virus, was serologically related but different from the cowpox virus. In the
absence of a known natural host, vaccinia has been considered to be a laboratory virus that may have
originated from mutational or recombinational events involving cowpox virus, variola viruses or some
unknown ancestral Orthopoxvirus. A favorite candidate for a vaccinia ancestor has been the horsepox
virus. Edward Jenner himself suspected that cowpox derived from horsepox and he also believed that
‘‘matter” obtained from either disease could be used as preventative of smallpox. During the 19th cen-
tury, inoculation with cowpox (vaccination) was used in Europe alongside with inoculation with horse-
pox (equination) to prevent smallpox. Vaccine-manufacturing practices during the 19th century may
have resulted in the use of virus mixtures, leading to different genetic modifications that resulted in
present-day vaccinia strains. Horsepox, a disease previously reported only in Europe, has been disappear-
ing on that continent since the beginning of the 20th century and now seems to have become extinct,
although the virus perhaps remains circulating in an unknown reservoir. Genomic sequencing of a horse-
pox virus isolated in Mongolia in 1976 indicated that, while closely related to vaccinia, this horsepox
virus contained additional, potentially ancestral sequences absent in vaccinia. Recent genetic analyses
of extant vaccinia viruses have revealed that some strains contain ancestral horsepox virus genes or
are phylogenetically related to horsepox virus. We have recently reported that a commercially produced
smallpox vaccine, manufactured in the United States in 1902, is genetically highly similar to horsepox
virus, providing a missing link in this 200-year-old mystery.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Vaccination was largely responsible for the eradication of small-
pox declared by the World Health Organization in 1980 [1]. Most
people are familiar with the work of Edward Jenner, who in 1798
published his famous work, often simply referred to as the
‘‘Inquiry”, reporting that the inoculation of cowpox protected
against smallpox [2]. Jenner called this new procedure ‘‘vaccine
inoculation”, to make reference to the cow (Lat. vacca), the pro-
posed origin of the preventative against smallpox. Richard Dun-
ning, a surgeon in Plymouth, coined the term vaccination in 1803
[3]. With the development of the germ theory of disease in the sec-
ond half of the 19th century, a large number of specific microor-
ganisms were identified as the etiological agents of different
human and animal diseases. At the 7th International Congress of
Medicine in London in 1881, to honor Jenner, Louis Pasteur pro-
posed to generalize the term ‘‘vaccination” to include all protective
immunization procedures against any infectious diseases [4,5].
A little-known fact is that Edward Jenner himself considered
that the preventative against smallpox which is present in cowpox
lesions, in fact derived from a disease of horses known as ‘‘grease”
(horsepox). Early in the 19th century, European physicians con-
ducted experiments that seemed to confirm the hypothesis that
horsepox could protect against smallpox. Because of the relative
rarity of cases of spontaneous cowpox, matter obtained from either
cowpox or horsepox was interchangeably used in the protection
against smallpox. Congruent with the use of the word vaccination,
the inoculation from the horse (Lat. equus) was referred to as
‘‘equination” [6–8].
For much of the 19th century the true nature of the preventa-
tive against smallpox was discussed among the medical commu-
nity, although it was usually assumed to be derived from cowpox
[9]. It is important to appreciate that although the broader concept
of transmissible agents of diseases was generally accepted by 19th
century science, the medical community had to wait until the end
of the century to have a clearer understanding of the role of
microorganisms in the causation of disease. Thus, smallpox vacci-
nation was developed and used in the 19th century based on
enlightened empiricism. Viruses were only identified at the very
end of the 19th century, based mainly on the criterion that their
small size allowed them to pass through filters known to retain
the smallest bacteria (filterable viruses).
The science of virology made considerable advances during the
first half of the 20th century, including the ability to multiply
viruses in embryonated eggs and tissue culture, thus allowing for
a more detailed characterization of their biological, biochemical
and immunological properties [10]. In 1939 Allan Watt Downie, a
Professor of Bacteriology at the University of Liverpool, using sero-
logical techniques, demonstrated that the contemporary virus used
for vaccination against smallpox, now referred to as vaccinia, was
different from cowpox virus [11,12], reopening the scientific dis-
cussion about the true origin of vaccinia [13]. Since a natural ani-
mal host is not known, vaccinia is frequently referred to as a
laboratory virus that could have originated from a still unidentified
animal Orthopoxvirus ancestor. Based on the historical record, sev-
eral investigators, especially the recently deceased Derrick Baxby
(1940–2017), then a Lecturer in Medical Microbiology at the
University of Liverpool, proposed that a presumed horsepox virus
could be the long-sought ancestor of vaccinia [14–18]. Horsepox
is a very rare disease that may have become extinct [19]. Fortu-
nately, samples from a 1976 case of horsepox from Mongolia were
used for genome sequencing, revealing that the horsepox virus is
genetically related to vaccinia and might even be one of its ances-
tors [16]. Subsequently, other investigators have reported that con-
temporary vaccinia strains may in fact represent viruses derived
from complex recombinational events between different strains
of vaccinia that may have included a horsepox virus ancestor
[20–22]. We recently reported that a smallpox vaccine commer-
cially produced in the United States in 1902 is closely related to
horsepox virus, confirming the hypothesis that at least some of
the early smallpox vaccines were based on horsepox virus [23].
Here we review the historical data on the early use of horsepox
to immunize against smallpox (equination), as well as relevant sci-
entific information regarding vaccinia virus and its two most likely
ancestors, cowpox and horsepox viruses, in an attempt to throw
light on a 200-year-old mystery, the origin of vaccinia.
2. The historical record on equination
2.1. Jenner used both vaccination and equination to protect against
smallpox
The ‘‘Inquiry”, the most important work of Edward Jenner, was
published in 1798 under the title of ‘‘An Inquiry into the causes and
effects of the variolæ vaccinæ, a disease discovered in some of the
western counties of England, particularly Gloucestershire, and
known by the name of the cow pox” [2]. After documenting a num-
ber of people in which previous infection with cowpox protected
against smallpox (or against inoculation of smallpox, an early pro-
phylactic procedure also known as variolation), on 14 May 1796,
Jenner inoculated an eight-year-old boy named James Phipps with
matter obtained from a cowpox pustule on the hand of Sarah
Nelmes, a dairy maid, who had been directly infected from a
cow. That was the first and best-known experimental inoculation
of cowpox done by Jenner. To confirm that the child was protected
against smallpox, he was variolated six weeks later without show-
ing any evidence of infection, providing the first experimental evi-
dence that cowpox elicits protection against smallpox. At a time
when the nature and properties of viruses were not known, Jenner
had the intuition that the cause of cowpox was related to that of
smallpox, and for this reason he invented the term of ‘‘variolæ vac-
cinæ”, or ‘‘smallpox of the cow”, to refer to cowpox.
Other authors have analyzed the strengths and weaknesses of
the arguments advanced by Jenner to promote the use of cowpox
as a preventative of smallpox [3,13,14,24–30] and those arguments
will not be repeated here. We will focus instead on those aspects of
the Inquiry that specifically relate to equination.
Jenner considered the question of the origin of ‘‘spontaneous”
cases of cowpox and he made the observation that such cases were
frequently observed in farms where the same workers took care of
diseased horses and milked cows. He suggested that these farm
workers were responsible for transferring the putative agent of
cowpox from horses to cows. In fact, on the second page of the
Inquiry [2], Jenner made the following comments: ‘‘There is a dis-
ease to which the Horse, from his state of domestication, is frequently
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subject. The Farriers have termed it the Grease. It is an inflammation
and swelling in the heel, from which issues ‘‘matter” possessing prop-
erties of a very peculiar kind, which seems capable of generating a dis-
ease in the Human Body (after it has undergone the modification
‘‘which” I shall presently speak of), which bears so strong a resem-
blance to the Small Pox, that I think it highly probable it may be the
source of that disease. In this Dairy Country a great number of Cows
are kept, and the office of milking is performed indiscriminately by
Men and Maid Servants. One of the former having been appointed to
apply dressings to the heels of a Horse affected with the Grease, and
not paying due attention to cleanliness, incautiously bears his part
in milking the Cows, with some particles of the infectious matter
adhering to his fingers. When this is the case, ‘‘it commonly” happens
that a disease is communicated to the Cows, and from the Cows to the
Dairy-maids, which spreads through the farm until most of the cattle
and domestics feel its unpleasant consequences. This disease has
obtained the name of the Cow Pox.”
The Inquiry reported 23 ‘‘cases”, either observations or experi-
mental inoculations, which Jenner used to provide objective evi-
dence for his hypothesis [2]. Sarah Nelmes was case XVI and
James Phipps (although his name was not given in the publication)
was case XVII. It is little known, however, that at least five of the 23
reported cases (XIII, XIV, XV, XVIII and XX) involved matter that
Jenner believed was directly or indirectly derived from horses. Case
XV acquired the disease directly from a horse, although twenty
years later he contracted smallpox, and Jenner speculated that
the protection afforded by matter derived from horses was incom-
plete, because the morbid material from the horse needs to first
infect ‘‘the nipple of the cow, and passed through that medium to
the human subject.” Case XX was William Summer, a child who
was inoculated with matter taken from the nipples of one infected
cow from a farm in which cowpox broke out, presumably through
contamination from an infected horse. The case of William Sum-
mers is made special by the fact that he was the source of a chain
of human-to-human transmission, which was one of the most
remarkable contributions of the Inquiry, and the observation that
initially allowed the vaccine to be extensively used throughout
the United Kingdom, Europe and the rest of the world.
The publication of the Inquiry was received with a mixture of
expectation, skepticism and criticism. On the one hand, vaccination
could represent a safer alternative to variolation, a procedure that
carried considerable risks for the individual (up to a 2% chance of
developing severe smallpox and dying) and for the population
(by starting smallpox epidemics) [24]. On the other hand, some
people argued that there were known cases in which previous
infections by cowpox did not confer protection against smallpox.
In this regard, Jenner went to extraordinary lengths to describe
that only the ‘‘true cowpox” was an effective preventative against
smallpox and no other disease of the cow that he referred to as
‘‘spurious cowpox”. Jenner was right in making this distinction,
because today we know of other diseases that could be confused
with cowpox, such as bovine mamillitis caused by bovine her-
pesvirus 2, milker’s nodule caused by a poxvirus of the genus Para-
poxvirus, or warts [31].
It has been said that after publishing the Inquiry, Jenner aban-
doned the hypothesis of the horse origin of the preventative against
smallpox. In fact, in his subsequent works about the smallpox vac-
cine, published between 1779 and 1801 [32–34], Jenner did not
make any explicit reference to the potential horse origin of cowpox.
The reality is that although in public Jenner downplayed a potential
role of grease, probably to avoid unnecessary distractions from his
main findings, in private he continued favoring the possibility that
horse grease could also be a preventative of smallpox.
Experimental confirmation of a potential horse origin of the
preventative of smallpox was complicated by Jenner’ confusing
grease (dermatitis verrucosa) with horsepox (variola equina),
which may have hampered a more systematical evaluation of the
potential role of horsepox, or its wider use as a preventative for
smallpox [35].
In a 1797 letter to Jean de Carro (a Geneva-born physician prac-
ticing in Vienna, who played an important role in introducing the
vaccine in Europe, the Near East and India) [36–38], Jenner
expanded on what he believed was the mechanism by which the
protective matter was transmitted from horses: ‘‘If the Cowpox be
unknown in the Country in which you dwell, I should presume that
Men Servants, who are employ’d among Horses, are not employ’d in
milking cows. In Ireland, & in Scotland, where the Men Servants do
not milk, the disease is also unknown. It is unlucky (if I am right in
my opinion of the origin of the disease) that we cannot communicate
it in a direct way from the Horse to the Cow”.
Jenner went back to his hypothesis of the horse origin of the
vaccine in an 1804 letter to the Geneva physician Alexander Mar-
cet: ‘‘There was a circumstance in my first publication which escaped
the attention of almost all my Readers, perhaps even you, and that is
my second Plate, which represents a Pustule on the arm from a virus
derived from the Horse & not the Cow (from case XVIII, John Baker)”
[39].
Jenner and other British physicians were commonly using
equine matter for inoculation without specifically mentioning it,
probably because vaccinators were comfortable with the concept
that all the vaccines against smallpox were one and the same,
regardless of their animal origin.
In a series of letters written in 1813 to James Moore, Director of
the National Vaccine Establishment in London, Jenner described his
use of equination [9]. In June 1813 he indicated that a Mr. Melon, a
surgeon of repute in Litchfield, ‘‘has sent me some of his equine virus,
which I have been using from arm to arm for these two months past,
without observing the smallest deviation in the progress and appear-
ance of the pustules from those produced by the vaccine” [39]. In a
follow-up letter to Moore, dated August 1813, Jenner stated that
‘‘I have been constantly equinating for some months, and perceived
not the smallest difference between the pustules thus produced and
the vaccine. Both are alike, because they came from the same source.”
According to Crookshank [9,40], a distinguished British bacteri-
ologist who 90 years after the publication of the Inquiry became
one of the severest critics of Jenner, Jenner had abandoned vaccina-
tion for Equination by 1817. In effect, in May 1817 Jenner provided
a stock of equine lymph to the National Vaccine Establishment,
which according to Baron was widely distributed [39].
2.2. Early independent evidence of the protective role of equination
The first independent evidence in support of a horsepox role in
the prevention of smallpox was published in 1801 by John Glover
Loy, a Yorkshire physician [41]. Loy described several cases of peo-
ple who became infected while treating horses suffering from
grease or of individuals inoculated with horse matter that had been
passaged in cows. Loy reported that the lesions produced had
exactly the appearance of genuine cowpox, and in many cases
the individuals were shown to be protected from variolation. A
most important observation made by Loy was that ‘‘two kinds of
Grease exist, differing from each other in the power of giving disease
to the human or brute animal”, an observation that mirrors Jenner’s
description of ‘‘true” and of ‘‘spurious” cowpox, which could
explain the lack of success of some earlier investigators who
attempted to equinate. The work of Loy was not in total agreement
with Jenner’s original hypothesis which required that the horse
matter was first modified by a passage in the cow before it could
fully function as a preventative of smallpox. Nevertheless, Jenner
considered that Loy’s work ‘‘decisively proves (his) early assertions”
about the horse origin of vaccinia, although Jenner never again
adopted the horsepox theory in his publications [14].
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Additional confirmation of the horsepox hypothesis was pro-
vided by Luigi Sacco, an Italian physician responsible for the early
introduction and widespread use of vaccination in Northern Italy
[42]. In a letter from Sacco to Jenner, dated 25 March 1803, he
explains that after reading the book by John Loy, he was encour-
aged to continue his own experiments to try to obtain the vaccine
from horses with grease. Sacco described two individuals who
became infected from horses with grease (referred to as ‘‘Giavardo”
in Sacco’s publications in Italian), from whom he inoculated chil-
dren and cows. Matter from the inoculated children was used to
vaccinate other children who, subsequently, became resistant to
variolation. With that experience, Sacco became convinced that
grease was the origin of the smallpox preventative and that a pas-
sage in cows was not necessary to confer the ability to protect
against smallpox. In the same letter, Sacco suggested to Jenner
that, perhaps, he should consider changing the name of vaccine
for that of equine [6,39].
2.3. Other historical observations
Although the use of cowpox as a vaccine against smallpox was
the method of choice during the 19th century, additional efforts
were made by some vaccinators to document that at least certain
forms of grease, those compatible with horsepox, could also be
used to protect against smallpox.
In a letter from the Geneva physician and vaccinator Jean de
Carro to Jenner, dated 21 June 1803, he describes the experiences
of a Monsieur La Font, a French physician established in Salonica
in Macedonia (in present-day Greece), who succeeded in inoculat-
ing two children with matter obtained from a horse suffering of
grease (that he called ‘‘Javart”), although no information was pro-
vided regarding its protective value against smallpox [39].
Luigi Sacco sent his horse-grease matter to Jean De Carro, in
Vienna, who used it freely and gave of it to others [43]. Many years
later, in 1825, De Carro, who frequently added to his signature
‘‘vaccinator et equinator”, wrote a letter to his Edinburgh Professor
of Anatomy, Alexander Monro (the third), indicating that ‘‘the mat-
ter used at Vienna from 1799 to 1825 was partly British vaccine, and
partly originated from the grease of a horse at Milan, without the
intervention of the cow. The effect was so similar in every respect that
they were soon mixed; that is to say, after several generations, and, in
the hands of innumerable practitioners, it was impossible to distin-
guish what was vaccine and what was equine” [43,44].
Additional reports came from Paris where in 1812 a coachman
became infected while dressing a horse affected with the grease,
fromwhom two children were vaccinated and from them a vaccine
stock was prepared to vaccinate many others [39,45].
Derrick Baxby mentioned that in the early 19th century many
equine strains were introduced in Great Britain and were used by
Jenner, but unfortunately no detailed accounts of their develop-
ment were published [14].
Edgar Crookshank [9] was unable to obtain any data on horse-
pox cases in Great Britain but he was able to document several
examples in France, including a large outbreak of grease at
Rieumes, near Toulouse, in 1860, where matter from affected
horses was successfully used to inoculate a cow and more than
200 children, inducing typical vaccine lesions that protected
against a challenge with ‘‘ordinary vaccine virus” [46]. Another
case of horsepox was documented in 1863 in Alfort, now a suburb
of Paris, where a student was contaminated from a horse and the
matter subsequently used to vaccinate a child. Another outbreak
of horsepox occurred in Toulouse in 1880, from which a heifer
and several children were vaccinated.
In 1889 Crookshank concluded that in Great Britain ‘‘it is more
than probable that some of the Jenner’s stocks of equine lymph are
still in use; but equination is not wittingly practiced, for it is com-
monly supposed that all the lymph employed for the purpose of
vaccination has been derived from Cow Pox. In France, on the other
hand, it is extensively employed” [9].
In 1887, Pierre-Victor Galtier, Professor at the Veterinary School
in Lyon, France, reported several cases of horsepox in the town of
Saint-Jean-de-Nay, in the French department of Haute-Loire, from
where matter was obtained to inoculate eventually hundreds of
children [47]. It is interesting that some French vaccinators argued
that the horsepox-originated vaccine could be passed from one calf
to another for at least eleven generations without losing potency,
while the cowpox material usually lost potency after only four pas-
sages [48].
Many different smallpox vaccine stocks from Europe were
introduced to the United States during the 19th century. It is com-
monly assumed that most vaccines used in the United States by the
end of the 19th century derived from the so called ‘‘animal vac-
cine” (which has never been passaged in humans) introduced in
1870 by the British-born Boston physician Henry Austin Martin,
reportedly originating from a spontaneous case of cowpox that
occurred in Beaugency, France, in 1866 [49,50]. However, Martin
reported that he had also used lymph ‘‘from a heifer inoculated from
a spontaneous case of ‘‘horse-pox”, the fully-proved origin of the dis-
ease as occurring in the cow‘‘ and that he ‘‘intend(ed) to continue
the propagation of the two ‘‘stocks”mentioned above” [51]. Since nei-
ther cowpox nor horsepox are found in the Americas, it is not clear
what the origin of Martin’s horsepox virus was.
A well-documented case of intentional equination happened in
Holland as late as 1914, when Professor De Jong, from the Univer-
sity of Leyden, observed an epizootic of pustular stomatitis (horse-
pox), providing matter which was successfully used to immunize
nine children [52].
Taken together, it is well documented by historical data that the
practice of equination was widely used by multiple physicians in
several countries across Europe to protect successfully against
smallpox.
3. A tale of three Orthopoxviruses
The development of the smallpox vaccine took place more than
100 years before the modern concepts of virology were estab-
lished. Nevertheless, Edward Jenner and other smallpox vaccine
researchers of the 19th century showed extraordinary capacity to
infer complex scientific facts from careful epidemiological and
clinical observations, including the identification of the immuno-
logical relationships that exist among cowpox, horsepox, vaccinia
and variola viruses. Today we know that variola, the agent of
smallpox, as well as the cowpox, vaccinia and horsepox viruses
are all immunologically related viruses grouped within the Ortho-
poxvirus genus of the Poxviridae family. Traditionally the diseases
they cause, and the associated viruses, were defined and named
after the most obvious affected host, such as cowpox for the virus
causing pocks in cows, or horsepox for that causing similar pathol-
ogy in horses [53].
3.1. Cowpox virus, a virus from Eurasian rodents
In Jenner’s time, cowpox was described as a disease character-
ized by the appearance of lesions which are successively papular,
vesicular and pustular, normally confined to the teats and udders
of the cows, that occurred sporadically or as epizootics [7,54]. It
is believed that the disease existed in Europe ‘‘from time immemo-
rial”, although it was the work of Edward Jenner that attracted
attention to this disease.
Although it is generally believed that the occurrence of cowpox
was not frequent in Great Britain at the end of the 18th century, in
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Gloucestershire alone, the county where Jenner conducted his
observations and experiments, there were at least ten cowpox epi-
zootics between 1759 and 1798, suggesting that such epizootics
occurred regularly [55]. In 1888, Edgar Crookshank published his
investigations of a cowpox outbreak in Wiltshire, a location rela-
tively close to Gloucestershire. He discarded the possibility that
the outbreak originated directly from horses and argued that the
main mode of dissemination was by mechanical transfer by milk-
maids from diseased horses to healthy cows, just as suggested by
Jenner almost 100 years earlier [56].
At the turn of the 19th to the 20th century, most human cases
of cowpox occurred among dairy farm workers, to the point that
cowpox was considered to be an occupational disease [57,58]. In
1977, Baxby reported 12 separate cases of confirmed cowpox
occurring in Great Britain between 1965 and 1976, ten of which
in humans, and conducted a serological survey among 1076 cows
in the same general region where the cowpox cases were
reported, finding that only 0.7% of them had Orthopoxvirus anti-
bodies. Baxby failed to identify the source of the human cases,
suggesting that small wild animals could play a role as hosts
and vectors of cowpox [59]. At the same time, other authors were
reporting that domestic cats were the most frequently recognized
host of the cowpox virus, raising the possibility that cats repre-
sented an intermediate host between hypothetical infected wild
rodents and humans [60]. Serological tests conducted among dif-
ferent species of rodents in various Eurasian countries confirmed
the hypothesis that different species of wild rodents serve as the
reservoir of Orthopoxviruses, including cowpox virus [60–63].
Cases of cowpox in cows have not been reported in the last few
decades in Great Britain, perhaps due to changes in animal hus-
bandry practices and the almost universal use of the vaccine for
most of the 20th century. In contrast to variola virus that can only
infect humans, cowpox virus has the broadest host range of all
known Orthopoxviruses [64], and an increasing number of cow-
pox cases have been described, not only in a variety of species
of wild rodents but also in cats, zoo animals and unvaccinated
humans in Europe.
Different strains of cowpox virus differ in their in vitro charac-
teristics and pathogenicity in mice [65,66], and one can only won-
der if those differences had also been important in the 19th
century in the voluntary or involuntary selection of the less reacto-
genic cowpox virus strains for vaccine use.
An additional level of diversity among cowpox viruses has been
shown by the phylogenetic analysis of their genomes [67–69].
Those studies indicate that cowpox viruses may not represent
one single virus species and that the different isolates in fact can
be grouped in at least three to five distinct clades. In this regard,
it has been pointed out that, despite the general belief that the
smallpox vaccine originated in the United Kingdom, the phyloge-
netic analysis shows that vaccinia strains map closer to Russian
and Finnish isolates of the cowpox virus, than to British isolates
[67].
3.2. Horsepox virus, a probably extinct virus
Ever since Jenner suggested in 1798that horse grease was the
origin of cowpox, the very existence of this disease has been mired
in controversy. This has led some modern authors to indicate that
‘‘Horsepox is a tantalizing disease for a modern virologist who is inter-
ested in the history of Jenner’s vaccine” [70].
Nevertheless, grease was known by Jenner’s contemporaries.
Writing in 1803, Henry Marie Husson, secretary of the Parisian
Medical Committee for the Inoculation of the Vaccine described
that ‘‘During the wet seasons, or well after long toils, horses are fre-
quently sick of a disease named ‘‘the grease” in English and ‘‘Eaux-
aux-Jambes” in French (water in the legs). It is a cutaneous disease,
generally chronic, sometimes inflammatory and contagious, never
acute, that affects the skin of the extremities of the horse, of the ass
and the mule, but rarely of the ox” [71,72].
In fact, grease heel, also known as dermatitis verrucosa or
chronic pastern dermatitis, has been known for centuries [73].
However, it has been argued that Jenner may have confused grease
with horsepox, or variolæ equinæ, also known as scratchy heel,
even though the two conditions were well known and recognized
at that time [35]. The confusion between the two diseases was
probably the reason for the early failures to reproduce Jenner’s
findings related to horsepox immunization, somehow clarified by
the work of John Loy in 1801 [41]. Equine pastern dermatitis is
not a single disease but a cutaneous reaction of the horse that
could be triggered by multiple causes, including genetic and envi-
ronmental factors, allergic reactions and multiple bacterial infec-
tions [74]. By 1863 Henry Marie Bouley and other French
veterinarians introduced the English term of horsepox to distin-
guish this disease from the syndromic equine pastern dermatitis
or eaux-aux-jambes [75].
Classical horsepox was considered to occur only in Europe, and
it was characterized by pox-like lesions in and around the mouth
and the legs of horses [76,77]. Like in the case of cowpox, cases
of horsepox were relatively uncommon even in Europe, and the
disease began to disappear from that continent at the end of the
19th century. The latest human cases of horsepox directly trans-
mitted from horses were reported from Great Britain early in the
20th century [78,79].
Although horsepox now seems to have become extinct in
Europe, severe cases of the disease were reported in the
Khentii province of Mongolia in 1976 [16]. However, in the
1980s, horsepox occurred only sporadically in Mongolia, especially
in the Domogovi, Dundgovi and Khentii provinces (Pip Beard and
Greg Gray, personal communication) [19]. Another potential
horsepox epizootic had originally been reported in the Uasin Gishu
county of Kenya in 1934, although the causative virus was not
genetically characterized [80,81]. Recent efforts to identify con-
temporary cases of horsepox anywhere in the world have failed
[19].
The only horsepox virus genome that has been sequenced is
from a 1976 isolate from Mongolia (MNR-76), revealing important
information regarding the genetic relationships of cowpox, horse-
pox and vaccinia viruses [16]. The horsepox virus genome
(212,633 base pairs) has an intermediate size between vaccinia
(177,923–194,711 base pairs) and cowpox (223,666–228,250 base
pairs) viruses, and a phylogenetic analysis of its central conserved
region revealed that horsepox virus is closely related to but distinct
from vaccinia. The authors concluded that while being closely
related to the known vaccinia-like virus, horsepox virus contains
additional, potentially ancestral sequences absent in other vaccinia
viruses. However, it is interesting to note that the horsepox virus
genome sequence has genes that are fragmented in some vaccinia
strains, but it also has fragmented sequences that are complete in
some other vaccinia strains [16]. This observation suggests that sev-
eral horsepox virus strains could have served as ancestors of differ-
ent vaccinia lineages.
We believe that the characterization of additional horsepox
virus isolates is needed to have a clearer idea of the phylogenetic
relationships of this virus with cowpox virus and their contribution
to the origin of the different lineages of vaccinia. Although the clin-
ical identification of new cases of horsepox is an obvious activity to
be conducted, we also believe that it is important to conduct sero-
logical and virological studies of relevant rodent populations
which, as in the case of cowpox, could serve as the virus reservoir
in nature [19].
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3.3. Vaccinia virus, the contemporary vaccine against smallpox
Vaccinia is the name given to the virus used to manufacture the
vaccine used to eradicate smallpox. The name obviously derives
from ‘‘variolæ vaccinæ”, or smallpox of the cow, the name that
Jenner invented to refer to cowpox, that for more than one 100
years was believed to be the preventative against smallpox [82].
The cowpox hypothesis was not without controversy and other
possibilities were advanced, including the one that the vaccine
was an attenuated form of variola [43,83–87]. In 1889 Taylor asked
the important question: ‘‘What is vaccinia? Is it cow-pox, or horse-
pox, or grease cow-pox, or horse-pox cow-pox, or small-pox cow-
pox?”, concluding that ‘‘One problem the Royal Commission on Vacci-
nation has to solve is, What is Vaccinia? If they solve this one point
only, their time will not be altogether wasted” [88].
The Italian microbiologist Adelchi Negri showed in 1905that
vaccinia passes through bacteriological filters [89,90], and in 1913
vaccinia was grown for the first time in the laboratory [91]. In
1922 vaccinia was purified using high-speed centrifugation [92]
and in 1940 DNA was shown to constitute its genetic material [93].
All the above research work was taking place while the field
could not agree on the true origin of vaccinia [94]. The discussion
was reopened when in 1939 Downie used a number of serological
tests (neutralization, agglutination and complement-fixation) to
compare two strains of vaccinia with two strains of cowpox virus,
reaching the conclusion that the virus causing spontaneous cow-
pox is not the same as the strains of vaccinia virus examined,
although the author could not discard a potential derivation from
variola [12]. In the late 1970s and mid-1980s, the true nature of
vaccinia began to be addressed by the genetic analysis of the virus
genomes. DNA endonuclease restriction site mapping confirmed
molecularly that cowpox, vaccinia and variola viruses were closely
related but distinct viruses [95,96], observations that were fully
confirmed by full genome sequencing [67–69,97,98].
Since no natural animal host is known for the vaccinia viruses,
two possibilities need to be considered to explain their origin: (1)
that they derive from a natural Orthopoxvirus, or (2) that they are
viruses unintentionally created in the uncontrolled manufacturing
processes used during the many years of production of smallpox
vaccines [99].
Regarding the existence of vaccinia-like viruses circulating in
nature, caution is needed in the interpretation of results because
the vaccinia-like viruses that have been reported are probably
derived from contemporary vaccinia strains. Vaccination against
smallpox has been practiced for more than 200 years, significantly
increasing during the intensified WHO smallpox campaign (1967–
1977). It is known that vaccinated individuals can accidentally
transmit vaccinia to contact animals, a situation that is facilitated
by the broad host range of vaccinia. Moreover, vaccinia ‘‘escapees”
have been able to initiate and maintain enzootic cycles in nature,
leading to epizootic infections in horses, cattle and other animals
caused by vaccinia-like viruses [100–106].
For most of the 19th century smallpox vaccine stocks were
maintained by serial arm-to-arm vaccination of children, using dif-
ferent sources of immunizing material, including cases of cowpox,
horsepox and even smallpox. This cumbersome procedure began to
be replaced as a source of vaccines after 1864 by the use of calves
that were vaccinated with matter that had been previously pas-
saged in humans. A further refinement was the adoption of the
so-called ‘‘animal vaccine” where cowpox matter taken directly
from one cow was used to inoculate and serially transfer the vac-
cine to other cows [107,108]. Those manufacturing developments,
and the ever-increasing need to produce large numbers of vaccine
doses demanded by the health authorities, led to the establishment
of numerous ‘‘vaccination farms” around the world, using in many
cases pools of different vaccine matter for the inoculation of calves
[49,109,110]. Animals were inoculated in multiple sites from
which material was collected when the lesions were judged to be
‘‘ripe” and the ‘‘pulp” ground in a mortar before being suspended
in diluent as vaccine ‘‘lymph” [1,111–114]. A survey conducted
by the World Health Organization (WHO) in 1967 revealed that
there were 67 producers of the smallpox vaccine in 45 countries,
with most of the producers using calves, a few using sheep or
water buffalo, and three of them using tissue culture or embry-
onated eggs [1]. The WHO then undertook efforts to modernize
and standardize the production of smallpox vaccines, resulting in
the identification of four strains that were widely used for wide-
spread vaccination: EM-63 (used mostly in the former USSR, said
to have derived from a strain from Ecuador), Lister (said to have
been originally isolated in Germany but manufactured in England),
New York City Board of Health, NYCBH (said to have been brought
from England to the US in 1856, and to be the reported parental
strain of all US-made smallpox vaccines), and Temple of Heaven
or Tiantan (used in China), although many other strains were also
used [1,115,116].
Recent genomic analyses have provided additional support for
the hypothesis that at least some vaccinia genes derived from
horsepox virus. Work published by the group of David Evans, in
Canada, suggests that the most probable route by which vaccinia
strains may have evolved is from a stock of virus containing an
ancestral horsepox-like virus. These findings are based on the iden-
tification of three genes (DVX_214 to DVX_216) present in the gen-
ome of horsepox virus, but absent in all known vaccinia strains,
except for two clones (DPP25 and CL3) of the Dryvax strain
[22,116]. Moreover, the phylogenetic analysis of the historical
smallpox vaccine used in Brazil until the late 1970s (strain IOC),
reportedly derived from the 1866 French Beaugency stock [50],
revealed that the strain IOC forms a novel cluster in the phylogeny
of the vaccinia lineage, which include vaccinia-IOC, the Brazilian
vaccinia field strains Cantagalo and Serro 2 viruses and horsepox
virus [20,117].
A more definitive evidence that horsepox virus was used com-
mercially to manufacture smallpox vaccines was the recent finding
by our group that an early smallpox vaccine, produced in 1902 by
H K Mulford of Philadelphia [118], is phylogenetically closer to
horsepox virus rather than to cowpox virus [23]. In addition, the
Mulford 1902 vaccine has two deletions in the telomeric regions
that are also found in current vaccinia, but not in cowpox or horse-
pox viruses, suggesting that the horsepox ancestor began to be
used as a smallpox vaccine many years before 1902, when the vac-
cine we characterized was manufactured.
4. Concluding comments
It is rather remarkable that vaccination against smallpox, a pre-
ventative intervention that was empirically developed at the end of
the 18th century, led to the eradication of one of the most feared
diseases at the end of the 20th century. In the absence of labora-
tory markers of immunogenicity, the smallpox vaccine was devel-
oped based on clinical observations, where success was defined by
the development in the vaccinated individual of skin lesions con-
sidered typical of cowpox, which were carefully described in the
contemporary literature. The ultimate efficacy test was the demon-
stration that vaccination protected the individual from variolation,
which basically was a challenge with the variola virus, a procedure
that could be practiced in Great Britain until variolation was out-
lawed by the Vaccination Act of 1840. Since variolation had been
the standard of smallpox prevention until vaccination became
widely available, it has been argued convincingly that Jenner’s
smallpox challenge experiments would have passed any hypothet-
ical ethical review conducted at that time [119].
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For the first 80–90 years of the vaccination enterprise, the
smallpox vaccine was carried and maintained by arm-to-arm inoc-
ulation of non-immune children. This cumbersome procedure was
not sustainable over time and carried the danger of transmitting
diseases such as syphilis. The manufacturing of the vaccine in
calves, from the 1860s onwards, was a major advance in the field.
However, in the absence of a clear understanding of the principles
of virology, which began to be developed only in the 20th century,
little attention was paid to careful identification of the source and
lineage of the material used to produce the vaccine. In this regard,
hearsays and legends replaced well-documented information, with
a romantic emphasis in tracing the source of many vaccines to the
original cowpox stock of Edward Jenner. In this regard, it is likely
that the horsepox origin of many vaccine stocks was hidden to
favor the preferred notion that cowpox was the authentic preven-
tative of smallpox. Modern genomic analyses are uncovering little
secrets of the past, as is the case of the Chinese smallpox vaccine
Tiantan, which has a typical vaccinia genome despite having a his-
tory of originating from a case of variola [120–122].
The Tiantan situation may be similar to many other smallpox
vaccines used around the world, all having a vague origin and pas-
sage history. That same belief was expressed by Edgar Crookshank
in 1889: ‘‘While attending at the National Vaccine Establishment of
the Local Government Board, I was unable to obtain any exact details,
clinical or pathological, of the source of the lymph which was
employed there. From my experience of this and other vaccination sta-
tions, I found that both official and unofficial vaccinators were com-
pletely occupied with the technique of vaccination, to the exclusion
of any precise knowledge of the history and pathology of the diseases
from which their lymph stocks had been obtained” [9].
Manufacturing practices in the pre-microbiological era may
have led to the intentional or unintentional mixing of vaccine
strains, both in human and animal hosts, resulting in horizontal
gene transfer and recombination between different Orthopox-
viruses [22,123–125]. The current vaccinia strains probably repre-
sent the result of multiple evolutionary lineages with sequences
derived from different ancestral viruses, including horsepox, which
we begin to understand only now. The fact that cowpox viruses
have the largest genome among all Orthopoxviruses has led to
the suggestion that an ancestral cowpox-like virus is the origin of
all Orthopoxviruses that have evolved, in part, by gene loss [126–
128]. It is likely that in the relatively long evolutionary history of
vaccinia, a few strains were unwittingly selected based on their
low reactogenicity, protective efficacy, stability and replication in
calves [129].
The phylogenetic analysis of vaccinia and other Orthopox-
viruses is complicated by the size and complexity of their genomes
[130], with conserved regions and variable telomeres that have
resulted from multiple recombinational events. Phylogenetic anal-
ysis has been used to classify Orthopoxviruses and define virus
species, departing from the traditional approach to name pox-
viruses based on the first identified animal species in which they
produce symptomatic disease [131]. Now we know that cowpox
virus is in fact a virus that infects rodents and a provocative sug-
gestion has been made, based on phylogenetic analysis, that the
different cowpox virus isolates may actually be reclassified into
three to five new species and, for historical reasons, to keep the
name of cowpox virus only for the clade that includes the isolates
from the United Kingdom [67]. What would be the future phyloge-
netic understanding of the horsepox viruses remains to be decided
if and when new isolates will be obtained from horses, wild
rodents or from another hitherto unknown reservoir.
In any case, even if there is increasing evidence that horsepox
virus had been used as a vaccine already in Jenner’s time, the origin
of the different lineages of vaccinia as well as its relationship to
cowpox and horsepox viruses is not accurately elucidated yet.
The possibility remains that a naturally occurring vaccinia virus,
now extinct, was an ancestor to extant vaccinia lineages, perhaps
modified by recombinational events with other Orthopoxviruses,
especially cowpox and horsepox viruses. Additional clues could
be obtained from ongoing work to characterize a number of histor-
ical specimens of smallpox vaccines [23].
An exciting development was recently achieved by the group of
David Evans, from Canada, with the in vitro construction of an
infectious horsepox virus from chemically synthesized DNA frag-
ments (David Evans, personal communication) [132]. The resulting
virus resembles vaccinia in many respects and its low virulence
suggested to the authors that the virus could represent a new gen-
eration of safer smallpox vaccines or vaccine vectors.
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